Comparison of alternative interpretive criteria for the HIV-1 Western blot and results of the Multispot HIV-1/HIV-2 Rapid Test for classifying HIV-1 and HIV-2 infections

Journal of Clinical Virology

Volumn 52, Issue SUPPL. 1, 2011, Pages

  Nasrullah, Muazzam ^a   Ethridge, Steven F ^a   Delaney, Kevin P ^a   Wesolowski, Laura G ^a   Granade, Timothy C ^a   Schwendemann, Joe ^b   Boromisa, Robert D ^b   Heffelfinger, James D ^a   Owen, S Michele ^a   Branson, Bernard M ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b WADSWORTH CENTER   (United States)

Author keywords

HIV subtype differentiation; HIV 1; HIV 1 Western blot criteria; HIV 1 HIV 2 Rapid Test; HIV 2; Supplemental HIV testing

Indexed keywords

CROSS REACTING ANTIBODY; GAG PROTEIN; POL PROTEIN;

ACCURACY; ARTICLE; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; IMMUNOASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MULTISPOT RAPID TEST; NONHUMAN; PRIORITY JOURNAL; VALIDATION PROCESS; VIRUS CLASSIFICATION; VIRUS IDENTIFICATION; WESTERN BLOTTING;

BLOTTING, WESTERN; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); CROSS REACTIONS; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; IMMUNOASSAY; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 80755141855     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.09.020     Document Type: Article

References (26)

1. Haute Autorite De Sante Public health guidelines: HIV infection screening in France, laboratory tests and algorithms 2008, Available from: http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-02/hiv_infection_screening_in_france_-_laboratory_tests_and_algorithms-conclusions.pdf [cited 07.09.10].
2. Constantine N., Saville R.D., Dax E.M. Retroviral testing and quality assurance 2005, Malloy Printers, Ann Arbor, MI, p. 322-323.
3. Torian L.V., Eavey J.J., Punsalang A.P., Pirillo R.E., Forgione L.A., Kent S.A., et al. HIV type 2 in New York City, 2000-2008. Clin Infect Dis 2010, 51(11):1334-1342.
4. Kumar L., Selik R. Epidemiology of HIV-2 infection in the U.S., 1996-2006 2007, Available from: http://www.hivtestingconference.org/hivtesting2007/powerpoint/1_Kumar.pps [cited 07.09.10].
5. Sullivan M.T., Guido E.A., Metler R.P., Schable C.A., Williams A.E., Stramer S.L. Identification and characterization of an HIV-2 antibody-positive blood donor in the United States. Transfusion (Paris) 1998, 38(2):189-193.
6. Irwin K.L., Olivo N., Schable C., Weber J.T., Janssen R., Ernst J. Absence of human immunodeficiency virus type 2 infection among patients in a hospital serving a New York community at high risk for infection. Centers for Disease Control and Prevention/Bronx-Lebanon Hospital Center HIV Serosurvey Team. Transfusion (Paris) 1996, 36(8):731-733.
7. O'Brien T.R., George J.R., Holmberg S.D. Human immunodeficiency virus type 2 infection in the United States. Epidemiology, diagnosis, and public health implications. JAMA 1992, 267(20):2775-2779.
8. De Cock K.M., Porter A., Kouadio J., Maran M., Lafontaine M.F., Gershy-Damet G.M., et al. Cross-reactivity on western blots in HIV-1 and HIV-2 infections. AIDS 1991, 5(7):859-863.
9. Ntemgwa M.L., d'Aquin Toni T., Brenner B.G., Camacho R.J., Wainberg M.A. Antiretroviral drug resistance in human immunodeficiency virus type 2. Antimicrob Agents Chemother 2009, 53(9):3611-3619.
10. O'Brien T.R., George J.R., Epstein J.S., Holmberg S.D., Schochetman G. Testing for antibodies to human immunodeficiency virus type 2 in the United States. MMWR Recomm Rep 1992, 41(RR-12):1-9.
11. Association of Public Health Laboratories and the Centers for Disease Control & Prevention HIV testing algorithms - a status report 2010, Available from: http://www.aphl.org/aphlprograms/infectious/hiv/Documents/StatusReportFINAL.pdf [cited 27.08.10].
12. Bio-Rad Laboratories Product insert, Human Immunodeficiency Virus Type 1, genetic systems HIV-1 Western blot 2004, Bio-Rad, Redmond, WA, USA.
13. Pandori M.W., Branson B.M. 2010 HIV diagnostics conference. Expert Rev Anti Infect Ther 2010, 8(6):631-633.
14. Bio-Rad Laboratories Product insert, Multispot HIV-1/HIV-2 Rapid Test 2004, Bio-Rad, Redmond, WA, USA.
15. Delaney K.P., Branson B.M., Uniyal A., Phillips S., Candal D., Owen S.M., et al. Evaluation of the performance characteristics of 6 rapid HIV antibody tests. Clin Infect Dis 2011, 52(2):257-263.
16. Torian L., Forgione L., Punsalang A., Oleszko W. Comparison of Multispot enzyme immunoassay with Western blot for confirmatory serodiagnosis of HIV. 18th conference on retrovirus and opportunistic infections 2011, Available from: http://www.retroconference.org/2011/Abstracts/41637.htm [cited 24.03.11].
17. Myers R. Identifying HIV-2 infections using a differential HIV-1 (gp41)/HIV-2 (gp36) serological assays (select HIV or Multispot) by testing HIV EIA reactive specimens unconfirmed as HIV-1 antibody positive by HIV-1 Western blot 2007, Available from: http://www.hivtestingconference.org/hivtesting2007/powerpoint/2_Myers.pps [cited 20.10.10].
18. U.S.Food and Drug Administration Complete list of donor screening assays for infectious agents and HIV diagnostic assays 2010, U.S. Department of Health and Human Services, Rockville, MD, Available from: http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/BloodDonorScreening/InfectiousDisease/ucm080466.htm [cited 12.11.10].
19. Owen S.M., Yang C., Spira T., Ou C.Y., Pau C.P., Parekh B.S., et al. Alternative algorithms for human immunodeficiency virus infection diagnosis using tests that are licensed in the United States. J Clin Microbiol 2008, 46(5):1588-1595.
20. Zaaijer H.L., v Exel-Oehlers P., Kraaijeveld T., Altena E., Lelie P.N. Early detection of antibodies to HIV-1 by third-generation assays. Lancet 1992, 340(8822):770-772.
21. 2010 HIV Diagnostics Conference 2007 HIV diagnostics conference summary 2010, Available from: http://www.hivtestingconference.org/confsum.html#_Toc192069911 [cited 09.09.10].
22. O'Conell R.J., Peel S.A. Multispot HIV-1/HIV-2 Rapid Test: advantages over other rapid HIV tests. Expert Rev Mol Diagn 2007, 7(5):499-505.
23. MacNeil A., Sarr A.D., Sankale J.L., Meloni S.T., Mboup S., Kanki P. Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection. J Virol 2007, 81(10):5325-5330.
24. Popper S.J., Sarr A.D., Gueye-Ndiaye A., Mboup S., Essex M.E., Kanki P.J. Low plasma human immunodeficiency virus type 2 viral load is independent of proviral load: low virus production in vivo. J Virol 2000, 74(3):1554-1557.
25. Popper S.J., Sarr A.D., Travers K.U., Gueye-Ndiaye A., Mboup S., Essex M.E., et al. Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J Infect Dis 1999, 180(4):1116-1121.
26. Andersson S., Norrgren H., da Silva Z., Biague A., Bamba S., Kwok S., et al. Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection. Arch Intern Med 2000, 160(21):3286-3293.